

NIH Public Access

Author Manuscript

J Psychiatr Res. Author manuscript; available in PMC 2010 November 29.

Published in final edited form as:

JPsychiatr Res. 2006 April; 40(3): 221–230. doi:10.1016/j.jpsychires.2005.09.007.

Computerized experience sampling method (ESMc): Assessing feasibility and validity among individuals with schizophrenia

David Kimhy^{a,b,*}, Philippe Delespaul^c, Cheryl Corcoran^{a,b}, Hongshik Ahn^d, Scott Yale^{a,b}, and Dolores Malaspina^{a,b}

^a Department of Psychiatry, Unit 2, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA ^b New York State Psychiatric Institute, New York, NY, USA ^c Departments of Psychiatry and Neuropsychology, Maastricht University, The Netherlands ^d Department of Applied Mathematics and Statistics, State University of New York, Stony Brook, NY, USA

Abstract

The Experience Sampling Method (ESM) is an ecologically valid, time-sampling of self-reports developed to study the dynamic process of person-environment interactions. ESM with digital wristwatch and booklets (paper-based ESM; ESMp) has been used extensively to study schizophrenia. The present study is designed to test the feasibility and validity of using Computerized ESM (ESMc) among individuals with schizophrenia. ESMc is advantageous in allowing for recording of precise time-stamps of responses. We used PDAs ("Personal Digital Assistant"; Palm handheld computers) to collect data on momentary psychotic symptoms, mood, and thoughts over a one day period among 10 hospitalized schizophrenia patients and 10 healthy controls. ESMc was equally acceptable to both groups, with similar ratings of comfort carrying the PDAs and operating them, interference with daily activities, as well as response rates. The schizophrenia patients reported significantly higher ratings of auditory and visual hallucinations, suspiciousness, sense of unreality, lack of thought control, fear of losing control, difficulty expressing thoughts, as well as depression/sadness, loneliness and less cheerfulness. Significant inverse relationships were found among both groups between ratings of feeling cheerful and being stressed, irritated, and sad/depressed. Among the schizophrenia subjects, the correlation between ratings of suspiciousness on ESMc and Scale for Assessment of Positive Symptoms (SAPS) approached significance, as well as the link between suspiciousness and stress. Our results support the feasibility and validity of using ESMc for assessment of momentary psychotic symptoms, mood, and experiences among individuals with schizophrenia. The authors discuss the potential applications of combining ESMc with ambulatory physiological measures.

Keywords

Schizophrenia; Psychosis; Experience sampling method (ESM); Palm handheld computers; Validity; Stress

1. Introduction

The Experience Sampling Method (ESM) is an ecologically valid, time-sampling of selfreports developed to study the dynamic process of person–environment interactions

^{© 2005} Elsevier Ltd. All rights reserved.

^{*} Corresponding author. Tel.: +1 212 543 6817; fax: +1 212 543 6176. dk553@columbia.edu. .

Kimhy et al.

(Delespaul, 1995). Subjects in ESM studies are typically supplied with digital wristwatch and booklets (paper-based ESM; ESMp) containing questionnaires about momentary thoughts, mood, and environmental context. The subjects are instructed to complete the questionnaire upon hearing beeps from the wristwatches, which are preprogrammed to beep randomly a number of times a day to elicit experience samples. Over the past decade, ESMp has been used extensively to study diverse psychiatric populations including individuals with schizophrenia (Delespaul, 1995; Delespaul et al., 2002; Myin-Germeys et al., 2000, 2001, 2002), psychosis (Myin-Germeys et al., 2003a,b, 2004), psychosis–proneness (Husky et al., 2004; Tournier et al., 2003; Verdoux et al., 2003), depression and bipolar disorder (Barge-Schaapveld and Nicolson, 2002; Barge-Schaapveld et al., 1995, 1999; Peeters et al., 2003; Swendsen and Compagnone, 2000; Wang et al., 2004), criminal offenders and violent psychiatric patients (Hillbrand and Waite, 1994; Hillbrand et al., 2000), as well as cannabis users (Tournier et al., 2003; Verdoux et al., 2003).

ESMp offers a number of advantages over interviews and retrospective data gathering methodologies including: (1) minimizing the potential risk of memory biases; (2) allowing ecologically valid assessment of experiences in real-world, real-time environments (i.e., in situ and in vivo); as well as (3) enabling to assess daily fluctuations in thoughts, mood, and symptoms as part of the continuous ebb and flow of person–environment interactions. However, investigations using ESMp cannot be certain of the exact time that the subjects actually completed their responses. They also do not have control over the order of the responses a subject chooses to complete on the questionnaire and the length of time they spend responding to each question. Furthermore, ESMp methodology makes it cumbersome to use branching – the presentation of different questions based on the subject's responses to previous items (i.e., if answer to question 4 is 'yes' then go to question 5, otherwise go to question 10).

The present study is designed to test the feasibility and validity of using computerized ESM (ESMc) among individuals suffering from schizophrenia. It uses PDAs ("Personal Digital Assistant"; Palm handheld computers) to collect data on psychotic symptoms, mood, thoughts, and experiences. ESMc offers a number of potential advantages over ESMp (Bolger et al., 2003; Stone and Shiffman, 2002) – (1) it provides direct measure of compliance by recording precise time-stamps for each response, as well as the time it took for the subject to complete each question; (2) ESMc facilitates the use of branching; (3) ESMc minimizes the cost and labor associated with transcription of data; and perhaps most importantly, (4) because of the availability of precise time-stamps, ESMc makes it feasible to investigate interactions between psychological and neurobiological mechanisms by synchronizing the times of ESMc and ambulatory physiological indexes (heart rate, electrodermal response, respiration, posture, movement, etc.). Additionally, Stone et al. (2003b) reported significantly higher compliance rates among users of electronic diaries, compared to paper-based diaries.

ESMc with PDAs has been used previously to assess clinical populations including individuals with chronic pain (Roelofs et al., 2004; Stone et al., 2003a), cancer (Gaertner et al., 2004), Parkinson's disease (Nyholm et al., 2004), and anhedonia (Kwapil et al., 2005). It also has been used to study anxiety, ADHD symptoms, and smoking and alcohol use among adolescents (Henker et al., 2002; Whalen et al., 2002). However, to our knowledge, this methodology has not been employed with individuals with severe psychiatric disorders, and in particular with individuals with schizophrenia. Thus, our goal is to study the feasibility and validity of using ESMc among individuals with schizophrenia.

2. Method

2.1. Participants

Twenty individuals participated in this preliminary study at the New York State Psychiatric Institute (NYSPI). The participants' demographic information is presented in Table 1. Ten patients with schizophrenia were recruited from the Schizophrenia Research Unit (SRU) – a psychiatric inpatient research unit. A sample of convenience of ten healthy controls was recruited from the medical center community. The healthy controls did not undergo assessment with the DIGS and SAPS. All subjects were aged between 18 and 55 and fluent in English. The study was approved by the NYSPI Institutional Review Board and all subjects provided written informed consent. Data were collected between July 2004 and January 2005.

2.2. Instruments

Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective

disorder—Diagnoses were made using the Diagnostic Interview for Genetic Studies (DIGS; Nurnberger et al., 1994), a structured diagnostic interview and medical records review that is used to gather diagnostic and course of illness information for the mood, psychotic, and substance use DSM-IV Axis I disorders. DIGS interviews were completed by a Master's level clinician blind to the present study.

Interview-based assessment of symptoms—Positive symptoms were assessed at admission to the SRU using the Scale for Assessment of Positive Symptoms (SAPS;Andreasen and Olsen, 1982) as part of standard research assessments at the SRU. The assessments were completed by a Master's level clinicians blind to the present study.

Self-reports of momentary psychotic symptoms, mood, thoughts, and

environmental contexts—Samples of psychotic symptoms, mood, thoughts, and environmental contexts were collected using self-report questionnaires completed on PDAs. The questionnaire was derived from previous ESM studies with individuals with schizophrenia and psychosis using ESMp (Delespaul, 1995; Myin-Germeys et al., 2000, 2001, 2002; Tournier et al., 2003; Verdoux et al., 2003). Table 2 presents the descriptions of the symptom and mood items assessed.

2.3. Procedure

Evaluations took place over a one-day period and were conducted during weekdays. On the morning of the study, participants completed a questionnaire about their knowledge, exposure, and previous experiences using PDAs. A brief introduction session followed in which subjects were introduced to basic operations of PDAs and completed two full practice sets of questions on the PDAs. The introduction sessions typically lasted about 15–20 min. Subjects were then provided with a Palm Tungsten T3 PDA (Palm OS ® version 5.2.1) to carry with them throughout the day. We used the *iESP* software (version 3.3; Intel Research Center, Seattle, WA) to present questions and collect responses on the PDAs. The PDA was pre-programmed to beep randomly 10 times between 10:00 am and 10:00 pm to elicit information about current psychotic symptoms, mood, thoughts, and social context. A stratified time sampling scheme was used to minimize the probability that activations will be concentrated over a short period of time. The software was set up to divide the assessment period (12 h) by the number of activations (10) to create 10 equal time-windows of 72 min each (12 h \times 60 min/10 beeps). It then scheduled one beep randomly within each timewindow. Thus, the potential period of time between activations ranged from 1 to 143 min. In accordance with previous ESM schizophrenia studies (Delespaul, 1995; Myin-Germeys et al., 2001), subjects had to complete at least 33% of the experience sampling activations in

order for their data to be considered valid and included in the data analyses. Upon hearing the beep, subjects were instructed to respond to a questionnaire presented on the screen of the PDA (i.e., "I feel stressed"; "My thoughts are suspicious"). For each symptom and mood question, subjects were asked to indicate on the PDA's screen the quality of their current experience on a graphical slider similar to a visual analog scale (from "not at all" to "very much"; See Fig. 1). Responses were represented in the output as a value between 1 ("not at all"; leftmost extreme) and 100 ("very much"; rightmost extreme). Additionally, subjects were asked about their current social context and activities (i.e., "I am with...?"; "what am I doing?"; see Fig. 2).

As the aim of ESMc is to assess momentary "live" experiences, subjects were given 180 s to respond to the activating beeps, as well as 180 s to complete each of the questions. If they did not complete their responses within this time period, the PDA was programmed to automatically turn off until the next activation. This limitation was put in place to minimize the possibility of memory bias influencing the experiences reported. To minimize the potential of the PDAs interfering with the subjects' normal daily activities and possibly impacting their responses, the PDAs were preprogrammed to be locked in-between activations for all basic PDA functions (calendars, to-do list, games, etc.), as well as access to the questions and previous responses. This locking procedure also ensured the privacy and confidentiality of subjects' responses during the day of data collection. For safety reasons, healthy controls were instructed not to respond to beeps while driving home from work. Following the completion of the 10 experience samples, subjects completed a questionnaire assessing their experiences using the PDA throughout the study day. The PDAs were collected from the subjects during the morning following the study day and the data was downloaded to a PC using standard PDA–PC data synchronization.

3. Statistical analyses

ESM data has a hierarchical structure in which repeated observations are nested within subjects and therefore are not independent. Since observations from the same subject are more similar than observations from different subjects, the residuals are not independent. Thus, to assess the relationships among symptoms and moods we analyzed the data using multilevel linear modeling. This method is more appropriate than conventional unilevel analyses for analyzing nested data (Schwartz and Stone, 1998). Multilevel modeling techniques are a variant of unilevel regression analyses (Hox, 2000), and they are standard for the analysis of ESM data (Gable et al., 2000). The multilevel data analyses were conducted using SAS software for Windows (version 9). The correlations among symptoms were estimated using the regression model for each pair of symptoms. Since the measures on each subject are repeated at different time points, and the data includes unequal cluster sizes due to the missing values for certain time points, we used Generalized Estimation Equation (GEE; Liang and Zeger, 1986) adjustment within the regression model to estimate the correlations. The variables were first standardized using mean and standard deviation. The correlation between two symptoms (or moods), a_i and a_j , is represented by the regression model,

 $a_i = \beta_0 + \beta_1 a_j + \epsilon$.

The GEE-adjusted β coefficient is taken from the model, with β_1 being the estimate for the correlation between the two symptoms. An autoregressive correlation structure is imposed since it is time-based within each individual. For comparisons between the schizophrenia and healthy controls group, the measurements on each subject's symptoms and moods are assessed using *z*-tests with *p*-values based on two-sided tests. Similar to the assessment of

relationships, the GEE-adjustment with an autoregressive correlation structure is imposed in order to take into account the dependence of the repeated measures within subject. This method is more effective and powerful than the *t*-test on the subjects' means across the time points because it allows use of the information from all the repeated measurements rather than an aggregate of them. The SD was calculated based on the mean value of the measurement for each subject. Comparisons of the groups' demographics and pre-and post-study response characteristics were calculated using *t*-tests.

4. Results

Thirteen individuals with schizophrenia were approached to participate in the study of which 11 agreed. In accordance with standards used in other ESM schizophrenia studies (Delespaul, 1995; Myin-Germeys et al., 2001), one subject's data was excluded from data analysis for completing fewer than 33% of the experience sampling activations, resulting in 10 valid protocols. Eleven healthy controls were approached to participate in the study of which 10 agreed.

Table 3 presents the pre- and post-study response characteristics for each group, as well as differences between the groups. Subjects from the schizophrenia and healthy controls groups provided on average 8.10 (SD = 1.79, range = 5–10) and 8.00 responses (SD = 2.05, range = 5–10), respectively. This difference was not significant (t(18) = 0.12, p = 0.91). The number of uncompleted responses due to the 180 s time restriction was minimal (schizophrenia = 4, healthy controls = 1). Data on five responses (schizophrenia = 2, healthy controls = 3) were lost due to an early software malfunction that was later corrected. Among the healthy controls average questionnaire completion time (from initial activating beep to completion time) was significantly faster (t(18) = 2.46, p = 0.02).

Prior to the study, subjects from both groups reported having limited familiarity with operating PDAs (M = 2.30, SD = 1.33 and M = 2.00, SD = 1.63, respectively) and moderate comfort levels operating them (M = 3.30, SD = 0.95 and M = 3.20, SD = 0.92, respectively). There were no significant differences between the groups in their familiarity with (t(18) = 0.45, p = 0.66) or comfort level of operating PDAs (t(18) = 0.24, p = 0.81). Likewise, following the study there were no significant differences between the groups in their reports of their ability to understand the presented questions, difficulties typing responses or operating the PDAs, or their level of comfort carrying the PDAs. The healthy controls characterized their participation in the study as significantly less challenging (t(18) = 2.63, p = 0.02).

Table 4 presents the means, standard deviation, and differences in symptom and moods between the healthy controls and individual with schizophrenia. As would be expected, individuals with schizophrenia reported significantly higher ratings of auditory and visual hallucinations, suspicious thinking, sense of unreality, lack of thought control, fear of losing control, difficulty expressing thoughts, as well as depression/sadness, lack of cheerfulness, and loneliness. There was no significant difference between the groups on ratings of level of stress, degree of being relaxed, and presence of racing thoughts. Among the schizophrenia patients, both psychotic symptoms and mood fluctuated considerably throughout the course of the day. Fig. 3 presents the temporal pattern of mean auditory hallucinations and sadness/ depression symptom ratings in schizophrenia patients and healthy controls across time of day. Interestingly, auditory hallucinations appeared to subside during 11 am–12 pm and 5 pm–6 pm periods, corresponding with lunch and dinner time at the unit (respectively). Similarly, among healthy controls, ratings of sadness/depression appear to subside between 12 pm and 1 pm and again between 4 pm and 6 pm, corresponding with lunch time and the end of the work day period (respectively).

As would be expected, inverse relationships were found for ratings of feeling cheerful and ratings of being stressed (r = -10.38, p < 0.001), irritated (r = -0.42, p < 0.0001), and sad/ depressed (r = -0.53, p < 0.0001) among both groups. Admission symptom ratings (SAPS) were available for nine of the 10 schizophrenia patients. The correlation between aggregated ESM rating of suspiciousness and ratings of suspiciousness on the SAPS (item #8) at admission approached significance (r = 0.61, p = 0.07, n = 9). Similarly, there was a trend for a relationship between degree of suspiciousness and levels of stress among the schizophrenia group (r = 0.30, p = 0.10, n = 9).

5. Discussion

Our results support the feasibility and validity of using ESMc for assessment of momentary psychotic symptoms, mood, and experiences among hospitalized individuals with schizophrenia. Our findings are particularly significant given the fact our subjects had no previous experience using PDAs. The ESMc methodology was equally acceptable to the patients with schizophrenia and healthy controls, with similar ratings of comfort carrying the PDAs, operating them, degree of interference with daily activities, as well as overall levels of stress and difficulties participating in the study. Equally important, both groups had similar response rates to the beeps.

The subjective nature of ESM data (e.g., thoughts, moods, mental states) makes the use of customary reliability and validity techniques problematic. The assessment of reliability is complicated by the fact that experiences assessed by ESMc, such as "I feel lonely", may not necessarily have behavioral expressions, thus making them difficult to verify. As a result, the ascertainment of reliability can be obtained only by evaluation of the validity (Delespaul, 1995). Once validity is demonstrated, reliability can be assumed. Delespaul (1995) suggested a number of methods to validate raw ESM data including the use of face validity, comparison of aggregated data between distinct groups, correlations between similar and dissimilar items, as well as determining associations with available behavioral/external referents.

In accord with these recommendations, we found ESMc to be valid. The items used in our assessment were designed to maximize face validity by using everyday vocabulary. A comparison of ratings of symptoms and mood between the subjects in the schizophrenia and healthy control groups indicate differences in the expected direction. Individuals with schizophrenia reported significantly higher ratings of auditory and visual hallucinations, suspicious thinking, sense of unreality, lack of thought control, fear of losing control, difficulty expressing thoughts, as well as depression/sadness, lack of cheerfulness, and loneliness. Similarly, the negative correlations between dissimilar items, such as feeling cheerful and feeling stressed, irritated, and sad/depressed support the discriminant validity of ESMc. The trend in the relationship between suspiciousness ratings on SAPS and ESMc give additional support for the validity of ESMc ratings among hospitalized patients with schizophrenia. However, the number of participants is small and should be considered preliminary.

The finding that there were no significant differences in ratings of stress between the schizophrenia and healthy control groups is noteworthy. Stress is common among individuals with schizophrenia (Kimhy et al., 2004; Steer et al., 2003) and has long been assumed to be associated with psychosis. Our findings suggest that schizophrenia patients

are not necessarily experiencing more stress, but rather their sensitivity to stress leads to exacerbation of psychotic symptoms.

Overall, we believe ESMc offers a number of advantages in research methodology. The most significant contribution of ESMc to research is in providing precise time-stamps for each response. By synchronizing the times of PDAs and ambulatory physiological measures, this feature makes it feasible to investigate interactions between psychological and neurobiological mechanisms. Thus, it offers exciting new ways to understand human behavior and functioning. In particular, this methodology has the potential to offer new insights into the mechanisms involved in psychopathology by studying the dynamic processes that govern the interactions between subjective experiences, neurobiology, and the environment. ESMc also limits the cost and labor associated with transcription and cleaning of data - (Nyholm et al., 2004) reported on a study of 20 subjects in which the total time required for data entry from paper-diaries was 96 person-hours compared to less than 4 person-hours for PDA diaries. However, the authors did not report the amount of time spent programming the PDAs. It is also important to note that data entered on a PDA by a subject may not be necessarily less susceptible to data-entry errors compared to data entered by a trained data entry person. Furthermore, there is no way for researchers to verify the correctness of data entered by subjects using ESMc after the data was collected. Finally, ESMc offers advantages with regard to study design and data management. In particular, the ability to limit the response time available to participants as well as branching are important features.

Potential limitations of this study should be acknowledged. The sample size in the present study was small and the assessment period was shorter than what is typical in ESM schizophrenia studies. Thus, the results should be interpreted with caution. A number of factors may have contributed to the higher response rate with ESMc compared to ESMp. Studies of individuals with schizophrenia using ESMp typically assess subjects 10 times per day from 7:30 am to 10:30 pm over 6 days (60 beeps). In contrast, the assessment period in the present study lasted only one day (10 beeps) from 10:00 am to 10:00 pm. Delespaul (personal communication) found that the average response rate among 50 individuals with schizophrenia studied over six days using ESMp was 72% during the first day of assessment, with the response rate gradually declining to 61% at day four and stabilizing afterwards. However, the majority of the missed beeps occurred in the early morning and late night periods that were not sampled in the present study. Thus, the relatively higher response rate using ESMc may reflect the initial higher response rate associated with the novelty of participating in an ESM research protocol and/or the designation of an assessment period that is characterized by a higher response rate. Similarly, participants in our study were presented with 27-32 ESM questions per beep (depending on branching) compared to approximately 50 in typical ESMp studies with individuals with schizophrenia (Delespaul, 1995; Myin-Germeys et al., 2000, 2001, 2002), which may have influence the response rate. Additionally, the current study was carried out in an inpatient unit, whereas most ESMp studies were carried out among outpatient individuals with schizophrenia. Such environment may potentially increase the risk of PDAs having malfunctions or being damaged, lost, or stolen. However, Kwapil (personal communication) reported only two PDAs being broken, none lost/stolen, and limited technical malfunctions in an ESMc study among approximately 400 college students.

An important question is the feasibility to using ESMc with patients with severe psychotic symptoms. While this methodology will clearly not be suitable for sampling with some schizophrenia patients, the hospitalized schizophrenia patients who participated in this pilot study were quite symptomatic, with mean SAPS ratings of psychotic symptoms ranging from mild to moderate (see Table 1), with many displaying marked and severe psychotic

symptoms. Consistent with this data, Delespaul (1995) and Myin-Germeys et al. (2001) has demonstrated extensively that ESM assessments are not restricted to small sub-samples of relatively asymptomatic schizophrenia patients.

In summary, assessment of momentary psychotic symptoms, mood, and experiences using ESMc is feasible among hospitalized schizophrenia patients. The methodology was acceptable to patients and caused minimal disruption in their daily activities and routines. The data also provide preliminary support for the validity of using ESMc in this population. Future studies should aim to replicate our findings with larger samples. Similarly, the feasibility of sampling experiences of over longer periods of time should be firmly established. Finally, future studies should also establish the feasibility of using ESMc with schizophrenia patients with more severe symptoms. Overall, ESMc is novel and exciting methodology that allows studying the dynamic processes that govern the interactions between subjective experiences, neurobiology, and the environment. Such knowledge may improve our understanding of mechanisms of development and resolution of psychopathology.

Acknowledgments

This work was supported by National Institute of Health Grant No. 1K24MH01699 (Dr. Dolores Malaspina).


References


- Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Archives of General Psychiatry 1982;39:789–94. [PubMed: 7165478]
- Barge-Schaapveld DQ, Nicolson NA. Effects of antidepressant treatment on the quality of daily life: an experience sampling study. Journal of Clinical Psychiatry 2002;63:477–85. [PubMed: 12088158]
- Barge-Schaapveld DQ, Nicolson NA, van der Hoop RG, De Vries MW. Changes in daily life experience associated with clinical improvement in depression. Journal of Affective Disorders 1995;34:139–54. [PubMed: 7665806]
- Barge-Schaapveld DQ, Nicolson NA, Berkhof J, DeVries MW. Quality of life in depression: daily life determinants and variability. Psychiatry Research 1999;88:173–89. [PubMed: 10622339]
- Bolger N, Davis A, Rafaeli E. Diary methods: capturing life as it is lived. Annual Review of Psychology 2003;54:579–616.
- Delespaul P, deVries M, Van OJ. Determinants of occurrence and recovery from hallucinations in daily life. Social Psychiatry and Psychiatric Epidemiology 2002;37:97–104. [PubMed: 11990012]
- Delespaul, P. Assessing schizophrenia in daily life. ISPER; Maastricht (The Netherlands): 1995.
- Gable SL, Reis HT, Elliot AJ. Behavioral activation and inhibition in everyday life. Journal of Personality and Social Psychology 2000;78:1135–49. [PubMed: 10870914]
- Gaertner J, Eisner F, Pollmann-Dahmen K, Radbruch L, Sabatowski R. Electronic pain diary: a randomized crossover study. Journal of Pain and Symptom Management 2004;28:259–67. [PubMed: 15336338]
- Henker B, Whalen CK, Jamner LD, Delfino RJ. Anxiety, affect, and activity in teenagers: monitoring daily life with electronic diaries. Journal of the American Academy of Child and Adolescent Psychiatry 2002;41:660–70. [PubMed: 12049440]
- Hillbrand M, Waite BM. The everyday experience of an institutionalized sex offender: an idiographic application of the experience sampling method. Archives of Sex Behavior 1994;23:453–63.
- Hillbrand M, Waite BM, Miller DS, Spitz RT, Lingswiler VM. Serum cholesterol concentrations and mood states in violent psychiatric patients: an experience sampling study. Journal of Behavioral Medicine 2000;23:519–29. [PubMed: 11199085]
- Hox, JJ. Multilevel analysis: techniques and applications. Lawrence Erlbaum Associates; Mahwah (NJ): 2000.


- Husky MM, Grondin OS, Swendsen JD. The relation between social behavior and negative affect in psychosis-prone individuals: an experience sampling investigation. European Psychiatry 2004;19:1–7. [PubMed: 14969774]
- Kimhy D, Harkavy-Friedman JM, Nelson EA. Identifying life stressors of patients with schizophrenia at hospital discharge. Psychiatric Services 2004;55:1444–5. [PubMed: 15572579]
- Kwapil TR, Silvia PJ, Myin-Germeys I, Brown LH, Anderson AJ, Coates SA. An experience sampling study of the relationship of social anhedonia with social contact, stress, and emotion. Schizophrenia Bulletin 2005;31:203.
- Liang, KL.; Zeger, SL. Longitudinal data analysis using generalized linear models. 1986. p. 13-22.
- Myin-Germeys I, Delespaul PA, DeVries MW. Schizophrenia patients are more emotionally active than is assumed based on their behavior. Schizophrenia Bulletin 2000;26:847–54. [PubMed: 11087017]
- Myin-Germeys I, Nicolson NA, Delespaul PA. The context of delusional experiences in the daily life of patients with schizophrenia. Psychological Medicine 2001;31:489–98. [PubMed: 11305857]
- Myin-Germeys I, Krabbendam L, Jolles J, Delespaul PA, Van OJ. Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. American Journal of Psychiatry 2002;159:443–9. [PubMed: 11870009]
- Myin-Germeys I, Krabbendam L, Delespaul PA, Van OJ. Do life events have their effect on psychosis by influencing the emotional reactivity to daily life stress? Psychological Medicine 2003a;33:327– 33. [PubMed: 12622311]
- Myin-Germeys I, Peeters F, Havermans R, Nicolson NA, De Vries MW, Delespaul P, Van OJ. Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatrica Scandinavica 2003b;107:124–31. [PubMed: 12534438]
- Myin-Germeys I, Krabbendam L, Delespaul PA, Van OJ. Sex differences in emotional reactivity to daily life stress in psychosis. Journal of Clinical Psychiatry 2004;65:805–9. [PubMed: 15291657]
- Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Archives of General Psychiatry 1994;51:849–59. [PubMed: 7944874]
- Nyholm D, Kowalski J, Aquilonius SM. Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease. Movement Disorders 2004;19:446–51. [PubMed: 15077243]
- Peeters F, Nicolson NA, Berkhof J, Delespaul P, deVries M. Effects of daily events on mood states in major depressive disorder. Journal of Abnormal Psychology 2003;112:203–11. [PubMed: 12784829]
- Roelofs J, Peters ML, Patijn J, Schouten EG, Vlaeyen JW. Electronic diary assessment of pain-related fear, attention to pain, and pain intensity in chronic low back pain patients. Pain 2004;112:335–42. [PubMed: 15561389]
- Schwartz JE, Stone AA. Strategies for analyzing ecological momentary assessment data. Health Psychology 1998;17:6–16. [PubMed: 9459065]
- Steer RA, Kumar G, Pinninti NR, Beck AT. Severity and internal consistency of self-reported anxiety in psychotic outpatients. Psychological Report 2003;93:1233–8.
- Stone AA, Shiffman S. Capturing momentary, self-report data: a proposal for reporting guidelines. Annals of Behavioral Medicine 2002;24:236–43. [PubMed: 12173681]
- Stone AA, Broderick JE, Schwartz JE, Shiffman S, Litcher-Kelly L, Calvanese P. Intensive momentary reporting of pain with an electronic diary: reactivity, compliance, and patient satisfaction. Pain 2003a;104:343–51. [PubMed: 12855344]
- Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Controlled Clinical Trials 2003b;24:182–99. [PubMed: 12689739]
- Swendsen JD, Compagnone P. The expression of cognitive vulnerabilities for depression in daily life: a French-American study. European Psychiatry 2000;15(Suppl. 1):22–8. [PubMed: 11520470]
- Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H. Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Research 2003;118:1–8. [PubMed: 12759155]

- Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine 2003;33:23– 32. [PubMed: 12537033]
- Wang PS, Beck AL, Berglund P, McKenas DK, Pronk NP, Simon GE, Kessler RC. Effects of major depression on moment-in-time work performance. American Journal of Psychiatry 2004;161:1885–91. [PubMed: 15465987]
- Whalen CK, Jamner LD, Henker B, Delfino RJ, Lozano JM. The ADHD spectrum and everyday life: experience sampling of adolescent moods, activities, smoking, and drinking. Child Development 2002;73:209–27. [PubMed: 14717253]

Kimhy et al.









Screen shot of a sample question (inpatients only).



Fig. 3.

Temporal pattern of auditory hallucinations and sadness/depression in schizophrenia patients and healthy control across time of day.

Table 1

Kimhy et al.

Demographics and clinical information

		Mean	SD	t	Ρ					
Age	Healthy controls	26.0	7.0	1.90	0.08					
	Schizophrenia	34.5	12.3							
Education (years)	Healthy controls	16.2	1.4	2.11	0.06					
	Schizophrenia	14.4	2.3							
Sex (female/male)	Healthy controls	6/4	,	,	ī					
	Schizophrenia	4/6								
Ever married (yes/no)	Healthy controls	2/8								
	Schizophrenia	2/8								
Ethnicity		Schiz	Schizophrenia	mia		Health	Healthy controls	s		
Asian			2				0			
Black/African-American	u		Ч				0			
Hispanic			1				з			
White			5				9			
Multi-Ethnic			Ч				-			
Age of 1st psychiatric	Healthy Controls							1		
Hospitalization	Schizophrenia				25.8 8.4	4				
Duration of Illness	Healthy controls			·				1		
	Schizophrenia				10.3 11	11.0			-	
Symptoms $(n = 9)$				Schiz	Schizophrenia			Healt	Healthy controls	slo
		Me	Mean	SD	Range	% Severe	Mean	SD	Range	% Severe
Auditory hallucinations		5.	2.78	2.63	0-5	56	,	1	ı	I
Visual hallucinations		.0	0.77	1.71	0-5	11		ī	,	ı
Delusions of persecution	и	5.	2.78	2.44	0-5	56	,	ī	ī	ī
Delusions of being controlled	rolled	ì	1.78	2.17	0-5	33	,	ı	·	·
Hallucinations (global rating)	ating)	ώ.	3.75	1.91	0-5	56		·	ı	ı
Delusions (global rating)	(1)	ώ.	3.77	2.17	0-5	LL		·	ī	ı
Bizarre behavior (global rating)	l rating)	. [.] 0	0.77	2.44	0-4	11	,	ī	ı	ı

J Psychiatr Res. Author manuscript; available in PMC 2010 November 29.

Healthy controls	Mean SD Range % Severe	
_	SD Range % Severe	44
izophrenia	Range	0-5
Schi	SD	2.28
	Mean	2.22
Symptoms $(n = 9)$		Positive formal thought disorder (global rating)

n = 20; DSM-IV diagnoses of the subjects in the schizophrenia group – 6 schizophrenia, 3 schizoaffective disorder, 1 schizophreniform disorder; symptom ratings are based on the Scale for Assessment of Positive Symptoms (SAPS) ranging from 0 (None) to 5 (Severe); % Severe – percent of patients with psychotic symptom rated as Marked or Severe (4 or 5).

Table 2

Description of the ESMc symptom and mood items

Symptoms and moods	Questions on PDA
Visual hallucinations	"I see things (that other people can't see)"
Auditory hallucinations	"I hear voices (that other people can't hear)"
Suspiciousness	"My thoughts are suspicious"
Thought control	"I'm in control of my thoughts"
Preoccupation	"I can't get rid of my thoughts"
Fear of losing Control	"I fear I would lose control"
Unreality	"I feel unreal"
Difficulty expressing thoughts	"My thoughts are difficult to express"
Confusion	"This thought is confused"
Stress	"I feel stressed"
Relaxation	"I feel relaxed"
Racing thoughts	"My thoughts are going too fast"
Sadness/depression	"I feel sad/depressed"
Irritation	"I feel irritated"
Cheerfulness	"I feel cheerful"
Loneliness	"I feel lonely"

Table 3

Means, SD, distribution and differences in experiences between healthy controls and individual with schizophrenia

				Mean	SD	<i>t</i> (18)	d
Questionnaire completion time (seconds from beep time to completion) ^{a}		Healthy controls		119.20	31.39	2.46	0.02
		Schizophrenia		159.87	41.68		
Number of completed questionnaires (out of possible 10)		Healthy controls	trols	8.00	2.05	0.12	0.91
		Schizophrenia	ia	8.10	1.79		
Distribution of completed questionnaires	Health	Healthy Controls			Schizol	Schizophrenia	
10 out of 10 questionnaires	ю				3		
9 out of 10 questionnaires	ю				5		
8 out of 10 questionnaires	0				1		
7 out of 10 questionnaires	1				2		
6 out of 10 questionnaires	1				1		
5 out of 10 questionnaires	2				1		
Pre-study questions							
I previously owned or currently own a PDA (yes/no)	Health	Healthy controls	1/9				·
	Schizo	Schizophrenia	0/10				
If yes - how long? (years)	Health	Healthy controls	S	ī	,		,
	Schizo	Schizophrenia	·				
I know how to operate a PDA	Health	Healthy controls	2.00	1.63	0.45		0.66
	Schizoj	Schizophrenia	2.30	1.33			
I feel comfortable operating a PDA	Health	Healthy controls	3.20	0.92	0.24		0.81
	Schizo	Schizophrenia	3.30	0.95			
Post-study questions							
I had difficulties understanding the questions	Health	Healthy controls	1.00	0.00	1.50		0.15
	Schizo	Schizophrenia	1.20	0.42			
I had difficulties typing my responses	Health	Healthy controls	1.30	0.67	0.27		0.79
	Schizo	Schizophrenia	1.40	0.97			
I had difficulties operating the PDA	Health	Healthy controls	1.00	0.00	1.50		0.15
	Schizo	Schizophrenia	1.20	0.42			
The PDA was comfortable to carry	Health	Healthy controls	3.40	1.07	1.98		0.06

NIH-PA Author Manuscript	NIH-PA Author Manuscript	uthor	AA	NIH-F	
Distribution of completed questionnaires	Healthy Controls			Schizophrenia	
	Schizophrenia	4.30	0.95		
The beeps interfered with my activities	Healthy controls	2.80	0.79	1.57	0.13
	Schizophrenia	2.20	0.92		
Overall, this experience was pleasant	Healthy controls	4.20	0.63	0.91	0.37
	Schizophrenia	3.80	1.23		
Overall, this experience was challenging	Healthy controls	1.40	0.70	2.63	0.02
	Schizophrenia	2.60	1.26		
Overall, this experience was stressful	Healthy controls	1.50	0.85	0.58	0.57
	Schizophrenia	1.70	0.67		
I would be interested to participate in similar studies in the future	Healthy controls	4.60	0.70	1.79	0.09
	Schizophrenia	3.80	1.23		
I would recommend to others to participate in a similar study	Healthy controls	4.80	0.42	1.71	0.10
	Schizophrenia	4.30	0.82		
n = 20; ratings on a 5-point Likert-scales (from 1 'not at all' to 5 'very much').	y much').				

NIH-PA Author Manuscript

Kimhy et al.

Table 4

Means, SD, and differences in symptoms and mood between healthy controls and individual with schizophrenia

Visual hallucinations Healthy controls 2.80 1.45 2.26 0.0237 Auditory hallucinations Healthy controls 2.82 1.52 3.94 <0.0001 Schizophrenia 81.88 $2.5.17$ 3.94 <0.0026 Suppiciousness Healthy controls 41.45 31.41 6.83 2.18 0.0296 Suppiciousness Healthy controls 7.17 6.85 3.94 <0.0001 Suppiciousness Healthy controls 7.17 6.85 3.94 <0.0001 Schizophrenia 31.51 5.72 3.94 <0.0001 Preoccupation Healthy controls 84.49 8.56 3.98 0.0172 Unreality Healthy controls 17.74 8.25 3.70 4.69 0.0075 Unreality Healthy controls 17.73 8.252 3.70 4.69 0.0075 Unreality Healthy controls 17.73 8.233 8.285 2.93 0.017 <			Mean	SD	Z score	d
Schizophrenia18.8 $2.5.17$ ny hallucinationsHealthy controls 2.82 1.52 3.94 Schizophrenia 41.45 31.41 Schizophrenia 41.45 31.41 Schizophrenia 7.17 6.85 2.18 Schizophrenia 20.67 17.24 8.56 3.98 In controlHealthy controls 7.17 6.85 3.98 Schizophrenia 20.67 17.24 8.56 3.98 Schizophrenia 20.67 17.24 8.56 3.98 Schizophrenia 17.74 8.27 1.43 Schizophrenia 31.51 25.74 4.69 Schizophrenia 17.39 12.86 2.38 Lily expressing thoughtsHealthy controls 5.05 3.70 4.69 Schizophrenia 17.39 12.86 2.393 2.016 Schizophrenia 28.82 23.93 2.143 2.016 Schizophrenia 28.35 23.93 2.143 2.128 Schizophrenia 28.35 23.93 2.169 2.349 Schizophrenia 28.32 23.93 2.143 2.128 Schizophrenia 28.62 2.33 2.143 2.166 Schizophrenia 28.82 2.33 2.143 2.143 Schizophrenia 28.32 2.333 2.143 2.143 Schizophrenia 28.32 2.349 2.340 Schizophrenia 2.333 2.441 2.340 Schizophrenia	Visual hallucinations	Healthy controls	2.80	1.45	2.26	0.0237
ry hallucinationsHealthy controls 2.82 1.52 3.94 $<$ iousnessHealthy controls 7.17 6.85 2.18 iousnessHealthy controls 7.17 6.85 2.18 iousnessHealthy controls 84.49 8.56 3.98 $<$ inpationHealthy controls 84.49 8.56 3.98 $<$ inpationHealthy controls 6.67 17.24 1.43 inpationHealthy controls 17.74 18.27 1.43 inpationHealthy controls 5.05 5.03 2.38 iny expressing thoughtsHealthy controls 5.05 3.70 4.69 iny expressing thoughtsHealthy controls 5.05 3.70 4.69 iny expressing thoughtsHealthy controls 9.82 8.38 2.80 iny expressing thoughtsHealthy controls 9.82 8.33 0.16 intoHealthy controls $3.9.42$ $1.8.31$ $1.7.41$ 1.21 stonHealthy controls $3.9.42$ $1.8.31$ $1.7.42$ $2.9.33$ intoHealthy controls $3.9.42$ 1.23 0.16 0.01 stonHealthy controls 5.05 3.70 4.69 0.01 stonHealthy controls $1.8.31$ $1.7.47$ 1.21 stonHealthy controls $2.3.65$ 3.70 4.69 0.01 stonHealthy controls 5.05 3.72 1.787 0.16 stoughts </td <td></td> <td>Schizophrenia</td> <td>18.88</td> <td>25.17</td> <td></td> <td></td>		Schizophrenia	18.88	25.17		
Schizophrenia 1.45 31.41 iousness Healthy controls 7.17 6.85 2.18 ktrontrol Healthy controls 7.17 6.85 2.18 ktrontrol Healthy controls 84.49 8.56 3.98 $<$ upation Healthy controls 84.49 8.56 3.98 $<$ schizophrenia 6.61 $8.57.4$ 1.43 $<$ $<$ ity Healthy controls 6.62 6.90 2.38 $<$ ity Healthy controls 6.62 6.90 2.38 $<$ ity Healthy controls 6.62 6.90 2.38 $<$ ity Healthy controls 17.30 12.86 $<$ $<$ ity Schizophrenia 18.30 8.86 $<$ $<$ $<$ ity Healthy controls 5.05 3.70 4.69 $<$ ity Schizophrenia 18.30 8.86	Auditory hallucinations	Healthy controls	2.82	1.52	3.94	< 0.0001
iousnessHealthy controls 7.17 6.85 2.18 kiousnessSchizophrenia 20.67 17.24 3.98 $<$ ht controlHealthy controls 84.49 8.56 3.98 $<$ schizophrenia 63.61 14.15 1.43 1.43 1.43 schizophrenia 31.51 25.74 1.43 1.43 schizophrenia 31.51 25.74 1.43 1.45 schizophrenia 31.51 25.74 1.46 $<$ lityHealthy controls 6.62 6.90 2.38 schizophrenia 17.30 12.86 3.90 2.66 lityHealthy controls 17.30 12.86 1.412 sionHealthy controls 5.05 3.70 4.69 $<$ lity expressing thoughtsHealthy controls 9.82 8.33 2.90 lity expressing thoughtsHealthy controls 1.830 8.86 2.393 sionHealthy controls 1.830 8.86 2.74 0.01 schizophrenia 2.066 2.303 2.303 0.16 schizophrenia 2.305 9.42 1.128 0.01 schizophrenia 2.305 9.73 0.16 schizophrenia 2.302 9.73 0.16 schizophrenia 2.302 1.178 0.01 schizophrenia 2.433 2.350 schizophrenia 2.433 2.340 schizophrenia 2.433 2.340 schi		Schizophrenia	41.45	31.41		
KurtonSchizophrenia 20.67 17.24 ht controlHealthy controls 84.49 8.56 3.98 schizophrenia 63.61 14.15 schizophrenia 63.61 14.15 schizophrenia 31.51 25.74 flosing controlHealthy controls 6.62 6.90 2.38 flosing controlHealthy controls 5.05 3.70 4.69 \sim lityHealthy controls 5.05 3.70 4.69 \sim schizophrenia 17.39 12.86 3.70 4.69 \sim lityschizophrenia 18.30 8.86 2.39 \sim lity expressing thoughtsHealthy controls 9.82 8.31 1.21 sionHealthy controls 3.942 11.88 0.01 lityschizophrenia 23.05 8.31 0.16 sionHealthy controls 52.94 9.73 0.16 sithoughtsHealthy controls 52.94 9.73 0.16 sthoughtsHealthy controls 24.33 23.40 onHealthy controls 26.62 1.97 0.16	Suspiciousness	Healthy controls	7.17	6.85	2.18	0.0296
In controlHealthy controls 84.4 8.56 3.98 \sim upationHealthy controls 17.74 18.27 1.43 Schizophrenia 31.51 25.74 18.27 1.43 f losing controlHealthy controls 6.62 6.90 2.38 f losing controlHealthy controls 6.62 6.90 2.38 lityHealthy controls 5.05 3.70 4.69 \sim litySchizophrenia 17.30 8.86 2.30 lity expressing thoughtsHealthy controls 9.82 8.36 2.80 sionHealthy controls 9.82 8.36 2.30 lity expressing thoughtsHealthy controls 9.82 8.30 2.101 sionHealthy controls 39.42 11.21 14.74 1.21 sionHealthy controls 39.42 14.12 14.12 sionHealthy controls 39.42 14.12 24.33 24.12 stdepresionHealthy controls 24.33 14.12 24.33 24.12 stdepresionHealthy controls 24.33 24.32 24.03 24.03 stdepresionHealthy controls 26.23 14.12 24.33 24.03 stdepresionHealthy controls 24.33 24.12 24.33 24.12 stdepresionHealthy controls 24.33 24.02 24.03 stdepresionHealthy controls 26.02 17.74 9.73 24.03 st		Schizophrenia	20.67	17.24		
schizophrenia 63.61 14.15 upation Healthy controls 17.74 18.27 1.43 flosing control Healthy controls 5.65 6.90 2.38 flosing control Healthy controls 6.62 6.90 2.38 ity Healthy controls 5.05 3.70 4.69 $<$ schizophrenia 17.39 12.86 2.38 2.80 ity Healthy controls 5.05 3.70 4.69 $<$ ity Expressing thoughts Healthy controls 9.82 8.86 2.30 sion Healthy controls 9.82 8.33 2.80 2.69 sion Healthy controls 11.83 14.74 1.21 schizophrenia 28.85 23.93 0.16 schizophrenia 28.85 23.93 0.16 schizophrenia 28.85 $2.3.93$ 0.16 schizophrenia 28.86 $2.5.24$ 0.16 schizophrenia 24.33 14.12 0.16	Thought control	Healthy controls	84.49	8.56	3.98	<0.0001
upationHealthy controls 17.74 18.27 1.43 closing controlBehlthy controls 5.62 6.90 2.38 f losing controlHealthy controls 5.05 3.70 4.69 $<$ kithHealthy controls 9.82 8.36 2.303 sionHealthy controls 9.82 2.393 2.80 kithHealthy controls $3.9.42$ 1.831 1.21 sionHealthy controls $3.9.42$ 1.831 0.01 kithHealthy controls $3.6.6$ $2.7.34$ 0.16 kithHealthy controls $3.6.37$ $2.7.33$ 0.16 kithSchizophrenia $3.6.86$ $2.5.24$ 0.01 soldepresionHealthy controls $2.9.32$ $2.3.30$ 0.16 soldepresionHealthy controls 2.028 $1.7.87$ 0.23 soldepresionHealthy controls $2.4.33$ $2.4.00$ 0.01 soldepresionHealthy controls $2.6.22$ 1.34 onHealthy controls $2.6.22$ 1.34 0.01 soldepresionHealthy controls $2.6.22$ 1.34 0.01 soldepresionHealthy controls <td< td=""><td></td><td>Schizophrenia</td><td>63.61</td><td>14.15</td><td></td><td></td></td<>		Schizophrenia	63.61	14.15		
Schizophrenia 31.51 25.74 f losing controlHealthy controls 6.62 6.90 2.38 lityBealthy controls 5.05 3.70 4.69 $<$ lityHealthy controls 5.05 3.70 4.69 $<$ lity expressing thoughtsHealthy controls 9.82 8.86 $<$ schizophrenia 18.30 8.86 2.30 $<$ sionHealthy controls 9.82 8.38 2.80 sionHealthy controls 9.82 8.36 2.30 sionHealthy controls 11.83 14.74 1.21 sionHealthy controls 39.42 11.88 0.01 utionHealthy controls 39.42 14.12 0.01 sthoughtsHealthy controls 36.86 25.24 0.16 sthoughtsHealthy controls 39.42 11.88 0.01 sthoughtsHealthy controls 20.28 14.12 0.016 sthoughtsHealthy controls 20.28 14.12 0.016 sthoughtsHealthy controls 20.28 17.87 0.23 sthoughtsHealthy controls 20.28 11.74 9.70 4.03 sthoughtsHealthy controls 26.62 15.46 1.34	Preoccupation	Healthy controls	17.74	18.27	1.43	0.1528
f losing controlHealthy controls 6.62 6.90 2.38 litySchizophrenia 17.39 12.86 4.69 $<$ lity expressing thoughtsHealthy controls 5.05 3.70 4.69 $<$ lity expressing thoughtsHealthy controls 9.82 8.86 $<$ sionHealthy controls 9.82 8.33 2.80 sionHealthy controls 11.83 14.74 1.21 sionHealthy controls 11.83 14.74 1.21 sionHealthy controls 39.42 11.88 0.01 stouphrenia 28.66 $2.5.24$ 0.01 stouphrenia 36.86 $2.5.24$ 0.01 stouphrenia 24.33 14.12 0.01 stouphrenia 24.33 14.12 0.01 stouphrenia 24.33 23.50 0.016 stouphrenia 24.33 23.50 0.016 stouphrenia 24.33 23.50 0.016 stouphrenia 24.33 23.50 0.016 stouphrenia 24.33 23.60 0.03 stouphrenia 26.62 15.46 1.34 onHealthy controls 26.62 15.46		Schizophrenia	31.51	25.74		
itySchizophrenia17.3912.86liyHealthy controls 5.05 3.70 4.69 liy expressing thoughtsHealthy controls 9.82 8.86 sionHealthy controls 9.82 8.33 2.80 sionHealthy controls 9.82 8.36 sionHealthy controls 11.83 14.74 1.21 sionHealthy controls 11.83 14.74 1.21 sionHealthy controls 39.42 11.88 0.01 Healthy controls 39.42 11.88 0.01 schizophrenia 36.86 25.24 0.16 schizophrenia 36.43 14.12 0.23 g thoughtsHealthy controls 52.94 9.73 0.16 stdepressionHealthy controls 20.28 17.87 0.23 stdepressionHealthy controls 24.33 23.50 4.03 onSchizophrenia 24.33 23.50 4.03 stdepressionHealthy controls 26.62 15.46 1.34 onSchizophrenia 36.10 23.40 2.55 inhessHealthy controls 26.62 15.46 1.34	Fear of losing control	Healthy controls	6.62	6.90	2.38	0.0172
lityHealthy controls5.053.704.69<ally expressing thoughtsHealthy controls9.828.862.80schizophrenia18.308.852.3931.01schizophrenia28.8523.931.21sionHealthy controls11.8314.741.21sionHealthy controls11.8314.741.21schizophrenia23.0518.311.21Schizophrenia23.0518.311.21schizophrenia35.8625.240.01schizophrenia54.3314.120.23sthoughtsHealthy controls20.2817.870.23sthoughtsHealthy controls20.2817.870.23sthoughtsHealthy controls24.3323.500.16sthoughtsHealthy controls20.2817.870.23sthoughtsHealthy controls24.3323.400.03sthoughtsHealthy controls26.6215.461.34onSchizophrenia36.1023.400.16sthousBealthy controls26.6215.461.34onHealthy controls26.6015.282.55wheresHealthy controls66.0915.282.55		Schizophrenia	17.39	12.86		
Schizophrenia18.308.86Ily expressing thoughtsHealthy controls9.828.382.80Schizophrenia28.8523.932.80Schizophrenia28.8523.9314.741.21Schizophrenia28.0518.3114.741.21Schizophrenia28.6625.240.01Schizophrenia36.8625.240.01Schizophrenia36.8625.240.16Schizophrenia36.8625.240.23sthoughtsHealthy controls54.3314.12sthoughtsHealthy controls20.2817.870.23sthoughtsHealthy controls20.2817.870.23sthoughtsHealthy controls21.3323.500stolepressionHealthy controls11.749.704.03onHealthy controls11.749.704.03stolepressionHealthy controls26.6215.461.34onSchizophrenia36.1023.401.34stolepressionHealthy controls26.6915.282.55uhessHealthy controls66.0915.282.55	Unreality	Healthy controls	5.05	3.70	4.69	< 0.0001
Ity expressing thoughtsHealthy controls9.828.382.80schizophrenia28.8523.9333sionHealthy controls11.8314.741.21schizophrenia23.0518.311.21Schizophrenia23.0518.310.01Healthy controls39.4211.880.01Schizophrenia36.8625.240.16Schizophrenia36.4314.120.16Schizophrenia54.3314.120.23stoughtsHealthy controls20.2817.870.23stoughtsHealthy controls24.3323.500.16stoughtsHealthy controls24.3323.500.13stoughtsHealthy controls26.6215.461.34onSchizophrenia36.1023.400.13storessionHealthy controls26.6215.461.34onSchizophrenia36.1023.481.34storessionHealthy controls26.6215.461.34onSchizophrenia36.1023.481.34storessionHealthy controls66.0915.282.55		Schizophrenia	18.30	8.86		
Schizophrenia 28.85 23.93 sion Healthy controls 11.83 14.74 1.21 Schizophrenia 23.05 18.31 1.21 Schizophrenia 23.05 18.31 1.21 Healthy controls 39.42 11.88 0.01 Schizophrenia 36.86 25.24 0.16 Schizophrenia 36.86 25.24 0.16 Schizophrenia 36.43 14.12 0.23 thoughts Healthy controls 54.33 14.12 0.23 sthoughts Healthy controls 20.28 17.87 0.23 sthoughts Healthy controls 24.33 23.50 0.16 stophresion Healthy controls 11.74 9.70 4.03 on Healthy controls 11.74 9.70 4.03 stophrenia 36.10 23.40 1.34 on Healthy controls 16.62 15.46 1.34 stophrenia 36.10 23.40 1.34	Difficulty expressing thoughts	Healthy controls	9.82	8.38	2.80	0.0052
sion Healthy controls 11.83 14.74 1.21 Schizophrenia 23.05 18.31 Healthy controls 39.42 11.88 0.01 Schizophrenia 36.86 25.24 ition Healthy controls 52.94 9.73 0.16 Schizophrenia 54.33 14.12 Schizophrenia 24.33 23.50 stdepression Healthy controls 11.74 9.70 4.03 schizophrenia 24.33 23.50 on Healthy controls 11.74 9.70 4.03 schizophrenia 36.10 23.48 indess Healthy controls 66.09 15.28 2.55 dented for 1.34		Schizophrenia	28.85	23.93		
Schizophrenia 23.05 18.31 Healthy controls 39.42 11.88 0.01 Kealthy controls 39.42 11.88 0.01 Schizophrenia 36.86 25.24 9.73 0.16 Schizophrenia 36.81 25.24 9.73 0.16 Schizophrenia 54.33 14.12 0.23 54.33 14.12 Schizophrenia 54.33 14.12 0.23 55.350 0.23 55.350 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.23 55.02 0.16 0.23 55.02 0.10 55.02 10.34 55.02 10.174 9.70 4.03 55.02 10.34 55.02 10.34 55.02 10.104 55.02 10.34 55.02 10.34 55.02 10.34 55.02 10.34 55.02 10.34	Confusion	Healthy controls	11.83	14.74	1.21	0.2264
Healthy controls39.4211.880.01Schizophrenia36.8625.24Schizophrenia36.8625.24Schizophrenia54.3314.12Schizophrenia54.3314.12Schizophrenia24.3323.50Schizophrenia24.3323.50Schizophrenia24.3323.50Schizophrenia24.3323.50Schizophrenia24.3223.40Nuthy controls11.749.70Schizophrenia36.1023.48Schizophrenia36.1023.48Schizophrenia36.1023.48Schizophrenia36.1023.48Schizophrenia36.1023.48Schizophrenia36.1023.48Schizophrenia36.0915.282.55Schizophrenia36.0915.282.55		Schizophrenia	23.05	18.31		
anSchizophrenia36.8625.24anHealthy controls52.949.730.16Schizophrenia54.3314.1214.12noughtsHealthy controls20.2817.870.23Schizophrenia24.3323.5011.749.704.03depressionHealthy controls11.749.704.03depressionHealthy controls11.749.704.03Schizophrenia41.9723.401.34Healthy controls36.1023.48nessnessHealthy controls66.0915.282.55	Stress	Healthy controls	39.42	11.88	0.01	0.9958
anHealthy controls52.949.730.16Schizophrenia54.3314.12Schizophrenia54.3314.12nughtsHealthy controls20.2817.870.23Schizophrenia24.3323.504.03depressionHealthy controls11.749.704.03Schizophrenia41.9723.4041.34Healthy controls26.6215.461.34Schizophrenia36.1023.48nessness		Schizophrenia	36.86	25.24		
Schizophrenia54.3314.12noughtsHealthy controls20.2817.870.23Schizophrenia24.3323.5024.035depressionHealthy controls11.749.704.035Schizophrenia41.9723.404.03555Healthy controls36.1023.481.34556.091.541.34nessHealthy controls66.0915.282.5513	Relaxation	Healthy controls	52.94	9.73	0.16	0.8687
noughtsHealthy controls20.2817.870.23Schizophrenia24.3323.50depressionHealthy controls11.749.704.03Schizophrenia41.9723.40Healthy controls26.6215.461.34Schizophrenia36.1023.48nessHealthy controls66.0915.282.55		Schizophrenia	54.33	14.12		
Schizophrenia24.3323.50depressionHealthy controls11.749.704.03Schizophrenia41.9723.40Healthy controls26.6215.461.34Schizophrenia36.1023.48nessHealthy controls66.0915.282.55	Racing thoughts	Healthy controls	20.28	17.87	0.23	0.8174
depression Healthy controls 11.74 9.70 4.03 < Schizophrenia 41.97 23.40 1.34 1.34 Healthy controls 26.62 15.46 1.34 Schizophrenia 36.10 23.48 1.34 ness Healthy controls 66.09 15.28 2.55		Schizophrenia	24.33	23.50		
Schizophrenia 41.97 23.40 Healthy controls 26.62 15.46 1.34 Schizophrenia 36.10 23.48 16.00 ness Healthy controls 66.09 15.28 2.55	Sadness/depression	Healthy controls	11.74	9.70	4.03	<0.0001
Healthy controls 26.62 15.46 1.34 Schizophrenia 36.10 23.48 ness Healthy controls 66.09 15.28 2.55		Schizophrenia	41.97	23.40		
Schizophrenia 36.10 23.48 Healthy controls 66.09 15.28 2.55	Irritation	Healthy controls	26.62	15.46	1.34	0.1812
Healthy controls 66.09 15.28 2.55		Schizophrenia	36.10	23.48		
	Cheerfulness	Healthy controls	60.09	15.28	2.55	0.0107

		Mean	SD	SD Z score	b
	Schizophrenia	46.11 19.14	19.14		
Loneliness	Healthy controls	10.29	10.29 5.68	2.69	0.0071
	Schizophrenia	35.15 26.41	26.41		

n = 20; ratings on a visual analog scale on a PDA (from 1 'I not at all' to 100 'very much'); p-values are based on two-sided tests; SD was calculated based on the mean value of the measurement for each subject.

Kimhy et al.